AllSci News
Imperagen closes GBP 5 million seed round for quantum-powered enzyme engineering
Imperagen closes GBP 5 million seed round to scale enzyme engineering platform
Immunovant posts hopeful data for FcRn inhibitor in rheumatoid arthritis post batoclimab failure
Immunovant (Nasdaq: IMVT) reported preliminary Week 16 data from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, showing ACR20, ACR50, and...
EpiCypher and New England Biolabs expand epigenomics tools partnership with international distribution
EpiCypher (Durham, NC) and New England Biolabs (Ipswich, MA) announced an expanded strategic partnership on covering co-development of next-generation epigenomics research tools…
Duke University supported with USD 1.17m from NIH for combined T cell and B cell HIV immunotherapy
Duke University has received a USD 1.17 million NIH R56 award from the National Institute of Allergy and Infectious Diseases to advance…
Duke University receives USD 1.81m NIH grant for LRRK2 kinase biomarker research in neurodegeneration
Duke University has received a USD 1.81 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to investigate how LRRK2...
University of Georgia receives USD 1.3m NIH grant for Parkinson's disease neuroinflammation research
University of Georgia has received a USD 1.3 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to investigate...
CureDuchenne makes second investment in Tevard Bio’s work on DMD suppressor tRNA therapy
CureDuchenne, the Newport Beach, California-based nonprofit venture philanthropy organization, has announced a second investment in Tevard Biosciences to support development of the…
Genethon and Ampersand partner on novel AAV vectors with enhanced tissue specificity
Genethon, the French rare disease gene therapy organization based in Évry, and Ampersand Biomedicines, a Boston-based Flagship Pioneering company, announced a research…
Hyundai Bio claims niclosamide offers hope of treating Ebola, hantavirus in preclinical assays
Hyundai Bioscience reported an Ebola virus IC50 of 0.125 μM for its broad-spectrum antiviral candidate XAFTY (niclosamide), according to a company press...
HAYA's HTX-001 targets cardiac fibrosis through WISPER lncRNA reprogramming in nHCM patients
HAYA Therapeutics has dosed the first cohort in the Phase I/IIa clinical trial of HTX-001, an antisense oligonucleotide targeting WISPER lncRNA in patients...
PharmAla Biotech grants Jupiter Neuro US rights to ALA-002 MDMA therapeutic for USD 100m
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF, Toronto) has signed a term sheet to grant Jupiter Neurosciences (Nasdaq: JUNS, Jupiter, Florida) exclusive,...
Eli Lilly adds non-viral genetic meds platform via USD 202m Engage Bio acquisition
Eli Lilly has acquired San Carlos, California-based Engage Biologics Inc. for up to USD 202 million in cash, adding the company's Tethosome non-viral DNA...
Dyne Therapeutics initiates Phase III FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy
Dyne Therapeutics (Nasdaq: DYN) has announced the initiation of the Phase III FORZETTO trial of zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular...
Remepy's drug-software combo produces significant symptoms reduction in Phase IIa Parkinson's disease trial
Remepy reported Phase IIa clinical trial results for Hybridopa (levodopa/carbidopa plus DopApp), its drug-software combination for Parkinson's disease,...
Forlong Bio secures USD 17.5m in Pre-B funding for cytokine pipeline advancement
Suzhou-based Forlong Biotechnology has closed a Series Pre-B financing round of approximately RMB 120 million (USD 17.5 million) to advance its IL-15 and...
The AllSci Brief
Free, systematic R&D and deal news. Daily.